Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling

Core Viewpoint - Moderna is facing a $5 billion patent-infringement lawsuit regarding its COVID-19 vaccine, Spikevax, which allegedly infringes on lipid nanoparticle technology patented by Genevant Sciences and Arbutus Biopharma [1]. Legal Proceedings - U.S. District Judge Joshua D. Wolson denied Moderna's request for summary judgment, allowing the jury to decide on the patent infringement claims [1]. - The judge emphasized the importance of patent law, stating that copying inventions is not permissible, even with expedited vaccine development under "Operation Warp Speed" [2]. Technical Aspects of the Case - The lawsuit centers on the delivery mechanism of the vaccine, specifically how Messenger RNA (mRNA) is protected by lipid nanoparticles, which are claimed to be patented by the plaintiffs [3]. - Arbutus Biopharma asserts that their research involved identifying specific "molar ratios" of lipids necessary for the vaccine's safety and efficacy [3]. Government Immunity Defense - Moderna's defense strategy included invoking section 1498, which protects government contractors from patent infringement lawsuits, arguing that the vaccine was developed under a federal program [4]. - However, the judge ruled that section 1498 applies only if the product was intended for the government itself, not the general public, which could expose Moderna to $5 billion in damages [5]. Patent Validity and Infringement - The jury will also evaluate the scientific validity of the patent claims and the concept of "literal infringement," with the judge allowing certain technical requests regarding how patent infringement can be established [6].